Seelos Therapeutics Inc (SEEL) Return on Assets ROA from the second quarter of 2024 to second quarter of 2023 and for the year 2024, Average High and Low, Fundamental Ratios from Jun 30 2024 to Jun 30 2023 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Seelos Therapeutics inc   (NASDAQ: SEEL)


Seelos Therapeutics Inc 's ROA from the second quarter of 2024 to the second quarter of 2023 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Seelos Therapeutics Inc 's ROA in the second quarter of 2024?
Seelos Therapeutics inc achieved a return on average assets (ROA) of 92.82 % in its second quarter of 2024 a new company high.

ROA has improved compared to -399.68% in the first quarter of 2024, due to net income growth.

However, within the Healthcare sector 12 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2024 quarter, so far to 63, from total ROA ranking in the first quarter of 2024 at 5108.

What is ROA?


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Assets (Jun 30 2024)
II. Quarter		 (Mar 31 2024)
I. Quarter		 (Dec 31 2023)
IV. Quarter		 (Sep 30 2023)
III. Quarter		 (Jun 30 2023)
II. Quarter
Y / Y Total Assets Change -79.97 % -84.72 % -76.18 % -84.65 % -77.43 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 4 -27 -38 -51 -81
Return On Assets (TTM) 92.82 % -399.68 % -321.27 % -316.84 % -328.75 %
SEEL's Total Ranking # 63 # 5108 # 5842 # 5266 # 5390
Total Assets (TTM) in million 2 4 5 6 12
Seq. Total Assets Change -34.08 % -33.33 % -12.87 % -47.7 % -49.71 %
Seq. Net Income Change - - - - -

SEEL's 5 Years Annual ROA >> Back to SEEL Management Effectiveness >> Compare SEEL ROA to its Competitors


Return On Assets Company Ranking
Within: No.
Industry # 7
Sector # 13
Overall # 62

Return On Assets Statistics
High Average Low
92.82 %
-157.44 %
-615.49 %
(Jun 30 2024)   (Mar 31 2019)





Financial Statements
Seelos Therapeutics Inc 's Assets $ 2 million SEEL's Balance sheet
Seelos Therapeutics Inc 's Income $ 2 million Quarterly SEEL's Income Statement
SEEL's Income by Division See SEEL's Income by Division



Annual Return On Assets (Dec 31 2023)
FY 2023		 (Dec 31 2022)
FY 2022		 (Dec 31 2021)
FY 2021		 (Dec 31 2020)
FY 2020		 (Dec 31 2019)
FY 2019
Y / Y Total Assets Change -76.18 % -72.76 % 377.31 % 57.66 % 195.11 %
Total Assets in million 5 23 84 17 11
Y / Y Net Income Change - - - - -
Net Income in million -38 -74 -66 -19 -51
Annual Return On Assets -699.19 % -323.28 % -79.1 % -109.19 % -461.92 %

SEEL's 5 Years Annual ROA >> Back to SEEL Management Effectiveness >> Compare SEEL ROA to its Competitors



More Return On Assets Ratios
SEEL's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
SEEL's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for SEEL's Competitors
Subscribers only: Roa for Seelos Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for SEEL's Customers

You may also want to know
SEEL's Roi SEEL's Inventory Turnover Ratio SEEL's Growth Rates SEEL's Dividend Comparisons
SEEL's Profitability Ratios SEEL's Asset Turnover Ratio SEEL's Dividend Growth
SEEL's Roe SEEL's Valuation Ratios SEEL's Financial Strength Ratios SEEL's Dividend Payout Ratio



Companies with similar Return On Assets at Jun 30 2024, within Healthcare Sector ROA
AnTix Holdings, Inc.  152.35 %
Northview Acquisition Corp  146.58 %
Alaunos Therapeutics Inc   117.98 %
Orgenesis Inc   95.19 %
Seelos Therapeutics inc   92.82 %
Roivant Sciences Ltd   79.95 %
WEED, INC.  67.86 %
Longduoduo Co Ltd  60.67 %
Camp4 Therapeutics Corporation  60.12 %
Tracon Pharmaceuticals Inc   57.29 %
Sbc Medical Group Holdings Incorporated  56.62 %
Earth Science Tech Inc   52.82 %
Guardion Health Sciences Inc   50.49 %
Mimedx Group Inc   46.15 %
Dariohealth Corp   43.99 %
Entera Bio Ltd   41.83 %
Siga Technologies Inc  39.58 %
Welsis Corp.  38.62 %
Entrada Therapeutics Inc   36.04 %
Protagonist Therapeutics inc   35.19 %
Pharmacyte Biotech Inc   33.64 %
Valion Bio Inc   29.54 %
Biomx Inc  29.32 %
Exelixis Inc   27.87 %
Elite Pharmaceuticals Inc   27.67 %
Idexx Laboratories Inc  25.79 %
Lantheus Holdings Inc   24.68 %
Lite Strategy Inc   24.32 %
Nrc Health  24.26 %
Cyclerion Therapeutics Inc   24.06 %

Date modified: 2026-09-26T07:29:26+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.